Key Highlights

  • Alphatec (NASDAQ:ATEC) fell between 36 percent and 38 percent on October 30, 2026 after third quarter Revenue of USD 221.2 million fell short of the company's own expectations, according to the company release and published market data.
  • Revenue still grew 13 percent from USD 196.5 million, but full-year 2026 revenue guidance is now about USD 862 million, and published coverage puts the earlier level near USD 882 million.
  • Adjusted EBITDA reached USD 38.3 million, a 17.3 percent Margin that is up 400 basis points from a year earlier, so profitability improved even though the Top Line slipped.
  • Ending cash was USD 79.9 million and free Cash Flow guidance is about USD 10 million, which leaves less room for error at Alphatec (NASDAQ:ATEC).

What Alphatec Reported

Alphatec (NASDAQ:ATEC) reported third quarter results on October 29, 2026, after the market close. Revenue was USD 221.2 million, up 13 percent, and surgical revenue of USD 202 million rose 14 percent, with surgical hardware adding USD 26 million. The GAAP net loss was USD 5.5 million, or USD 0.03 per share, while non-GAAP Net Income was USD 14.8 million. Chairman and CEO Pat Miles said revenue fell short of expectations, primarily because of lower Biologics attachment. Published coverage also cites case Volume growth of about 20 percent and revenue per case down about 5 percent, a mix that points to pricing or product mix pressure and explains why revenue lagged case growth.

Why Biologics Attachment Matters

Biologics are bone graft products that surgeons often use alongside spinal implants. When fewer of them are attached to each procedure, revenue per case falls even if the number of surgeries rises. That appears to be the pattern at Alphatec (NASDAQ:ATEC), where management also pointed to slower thoracolumbar procedure volumes, which cover mid and lower back surgery. The new 2026 outlook calls for about USD 862 million of revenue, including about USD 789 million from surgical products, adjusted EBITDA of about USD 137 million and free cash flow of about USD 10 million. The USD 20 million trim is about 2.3 percent of USD 882 million, simple arithmetic on two published numbers.

Risks and What to Watch

The first risk is further estimate cuts if biologics attachment does not recover. A second is liquidity: cash of USD 79.9 million is about half the year-end 2025 balance, according to published coverage, and the free cash flow target is smaller than the roughly USD 20 million described in January. Competition among spine device makers and surgeon adoption of new systems also affect Alphatec (NASDAQ:ATEC). Investors should compare each figure here with the company filing, watch analyst rating changes after the drop, and look for biologics and thoracolumbar commentary at the next quarterly report. Share moves differ by timestamp, so the 36 percent to 38 percent range is a snapshot.

Where Things Stand

The company is Alphatec (NASDAQ:ATEC), which fell sharply because third quarter revenue missed the company's own plan and the full-year outlook was trimmed to about USD 862 million. The drop looks large against 13 percent revenue growth and a wider 17.3 percent adjusted EBITDA margin, but biologics attachment, slower back surgery volumes and thinner cash explain part of the reaction. The evidence is mixed rather than conclusive, and the next catalyst is the fourth quarter report, where recovery in revenue per case will be the key test.